Anti-OX40 binding proteins
The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.
1. A method for enhancing T cell activation in a subject with cancer, the method comprising administering to the subject an effective amount of an isolated anti-OX40 antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 24, and comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 25, or an antigen-binding fragment thereof.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, colorectal cancer, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, glioma, glioblastoma, esophageal cancer, liver cancer, kidney cancer, stomach cancer, colon cancer, cervical cancer, uterine cancer, liver cancer and a hematological cancer.
3. The method of claim 1 , wherein the cancer is selected from the group consisting of B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia (HCL), myeloproliferative disorder/neoplasm (MPDS), myelodysplasia syndrome, non-Hodgkin's lymphoma (NHL), including Burkitt's lymphoma (BL), Waldenstrom's Macroglobulinemia, mantle cell lymphoma, AIDS-related lymphoma, Hodgkin's Lymphoma (HL), T cell lymphoma (TCL), multiple myeloma (MM), plasma cell myeloma, plamocytoma, giant cell myeloma, heavy-chain myeloma, and light chain or Bence-Jones myeloma.
4. The method of claim 1 , wherein the anti-OX40 antibody is a human antibody.
5. The method of claim 1 , wherein the anti-OX40 antibody is an IgG.
6. The method of claim 1 , wherein the anti-OX40 antibody is an IgG1, IgG2, IgG3 or an IgG4 isotype.
7. The method of claim 1 , wherein the antigen-binding fragment is a Fab fragment or an scFv.
8. A method for stimulating 0X40 signaling in T cells in a subject, the method comprising administering to the subject an effective amount of an isolated anti-OX40 antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 24, and comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 25, or an antigen-binding fragment thereof; wherein the subject has a disease selected from the group consisting of cancer, an inflammatory disease, and an infection.
9. The method of claim 8 , wherein the inflammatory disease is selected from the group consisting of allergy, COPD, autoimmune disease, rheumatoid arthritis, asthma, graft versus host disease, Crohn's disease, ulcerative colitis, type-1 diabetes, multiple sclerosis, Systemic lupus erythematosis, lupus nephritis, Myasthenia Gravis, Grave's disease, transplant rejection, Wegener's granulomatosis, Henoch-Schonlein purpura, systemic sclerosis, and viral-induced lung inflammation.
10. The method of claim 8 , wherein the infection is a viral infection.